Caplight Logo









Serum Institute of India

Serum Institute of India

Private
Pune, MaharashtraHealthcare & Life Scienceshttps://www.seruminstitute.com

Last Round

Grant

Jan 23, 2024

Total Funding Raised

$585.89M

Company Overview

Serum Institute of India Pvt. Ltd. (SII) is an Indian multinational biotechnology and biopharmaceuticals company founded in 1966 by Dr. Cyrus Poonawalla. It is the world's largest vaccine manufacturer by the number of doses produced and sold globally, with more than 1.5 billion doses annually. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by the company. The company's mission was to make life-saving immuno-biologicals affordable and accessible, which were previously imported into India at high prices. Its product portfolio includes vaccines for polio, diphtheria, tetanus, pertussis, Hib, BCG, r-Hepatitis B, measles, mumps, rubella, and COVID-19. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization (WHO) and are used in national immunization programs in about 170 countries. Headquartered in Pune, India, the company is part of the privately-held Cyrus Poonawalla Group. In addition to its primary manufacturing operations, the company also makes strategic investments in other firms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

vaccine manufacturinglarge-scale manufacturinglow-cost vaccinesbiopharmaceuticalsbiopharmaglobal vaccine supplyimmunobiologicalsgovernment contractsB2GWHO prequalificationanti-serasnake antivenomCOVID-19 vaccinechildhood immunizationsHPV vaccineMalaria vaccinevaccine developmentcontract manufacturingCDMO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Serum Institute of India Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Serum Institute of India Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantJan 23, 2024
GrantApr 19, 2021
GrantOct 1, 2020
GrantSep 29, 2020
Private EquitySep 22, 2015
Grant
Nov 1, 2012

Serum Institute of India Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 29, 2026

    Collaborating with Oxford University on malaria vaccine R78C.

  • Apr 29, 2026

    Collaborating with Oxford University on a new malaria vaccine, R78C.

Serum Institute of India Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Serum Institute of India Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Serum Institute of India's valuation, stock price, and market status.

Firmographic Details

HeadquartersPune, Maharashtra
Employee Range6,803
Year Founded1966
Last FundingJan 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.